本研究旨在深度剖析长链非编码RNA P53和P21在大鼠动脉粥样硬化模型中的作用及应用潜能。择取60只大鼠,随机平均划分为正常组与粥样硬化组,借由构建大鼠动脉粥样硬化模型,综合运用多种实验技术(如免疫组织化学染色、实时荧光定量PCR、...本研究旨在深度剖析长链非编码RNA P53和P21在大鼠动脉粥样硬化模型中的作用及应用潜能。择取60只大鼠,随机平均划分为正常组与粥样硬化组,借由构建大鼠动脉粥样硬化模型,综合运用多种实验技术(如免疫组织化学染色、实时荧光定量PCR、蛋白质印迹法、酶联免疫分析等)及仪器(如彩色多普勒超声诊断仪),对两组中P53和P21的表达状况、调控机制及其与疾病演进的关联予以系统性且全方位的解析。研究成果有望为动脉粥样硬化的诊断与治疗提供新颖且极具价值的靶点与策略。This study aims to deeply analyze the role and application potential of long non-coding RNA P53 and P21 in rat atherosclerosis model. 60 rats were selected and randomly divided into normal group and atherosclerosis group. By constructing rat atherosclerosis model, a variety of experimental techniques (such as immunohistochemistry staining, real-time fluorescence quantitative PCR, protein blotting, enzyme-linked immunosorbent assay, etc.) and instruments (such as color Doppler ultrasound diagnostic instrument) were used to systematically and comprehensively analyze the expression status, regulatory mechanism and relationship between P53 and P21 and disease progression in the two groups. The research results are expected to provide novel and valuable targets and strategies for the diagnosis and treatment of atherosclerosis.展开更多
文摘本研究旨在深度剖析长链非编码RNA P53和P21在大鼠动脉粥样硬化模型中的作用及应用潜能。择取60只大鼠,随机平均划分为正常组与粥样硬化组,借由构建大鼠动脉粥样硬化模型,综合运用多种实验技术(如免疫组织化学染色、实时荧光定量PCR、蛋白质印迹法、酶联免疫分析等)及仪器(如彩色多普勒超声诊断仪),对两组中P53和P21的表达状况、调控机制及其与疾病演进的关联予以系统性且全方位的解析。研究成果有望为动脉粥样硬化的诊断与治疗提供新颖且极具价值的靶点与策略。This study aims to deeply analyze the role and application potential of long non-coding RNA P53 and P21 in rat atherosclerosis model. 60 rats were selected and randomly divided into normal group and atherosclerosis group. By constructing rat atherosclerosis model, a variety of experimental techniques (such as immunohistochemistry staining, real-time fluorescence quantitative PCR, protein blotting, enzyme-linked immunosorbent assay, etc.) and instruments (such as color Doppler ultrasound diagnostic instrument) were used to systematically and comprehensively analyze the expression status, regulatory mechanism and relationship between P53 and P21 and disease progression in the two groups. The research results are expected to provide novel and valuable targets and strategies for the diagnosis and treatment of atherosclerosis.
